Skip to content
Open access

One-Year Clinical Outcomes of Paclitaxel-Coated Balloon Angioplasty in Patients With and Without Acute Coronary Syndrome: The ALLIANCE Registry.

Oct 2026 · Catheterization and cardiovascular interventions · 0 citations · 28 references
Medicine

Abstract

Background

Real-world data after percutaneous coronary intervention (PCI) using drug-coated balloons (DCBs) in acute coronary syndrome (ACS) are limited.

Aims

We compared 1-year clinical outcomes after PCI with paclitaxel DCBs between the ACS and non-ACS patients.

Methods

The ALLIANCE is a prospective, multicenter registry of PCI using paclitaxel DCBs. Primary endpoint was target lesion failure (TLF), defined as a composite of cardiac death, myocardial infarction (MI), or clinically driven target lesion revascularization. Secondary endpoints included all-cause mortality at 1 year. Adverse events were adjudicated by an independent committee. Propensity score matching was performed to adjust for baseline differences between the ACS and non-ACS patients.

Results

From July 2023 to February 2024, 1794 patients with de novo lesions (ACS 513 [28.6%] and non-ACS 1281 [71.4%]) were enrolled at 57 medical institutions in Japan. Mean age was 71 years, and 76% were male. Among ACS patients, 34.7% had ST-segment elevation MI, 33.9% non-ST-segment elevation MI, and 31.4% unstable angina. Intracoronary imaging was used in 88.5% of lesions. Bailout stenting after DCB angioplasty was required in only 1.1% of 1984 lesions. Technical success, defined as post-procedural residual stenosis < 40% and absence of flow-limiting coronary dissection, was significantly lower in patients with ACS than those with non-ACS. At 1 year, TLF occurred in 7.0% of ACS and 3.8% of non-ACS patients (adjusted HR 1.83; 95% CI 1.06-3.17, p = 0.03). All-cause mortality was 6.4% and 3.3%, respectively (adjusted HR 2.06; 95% CI 1.13-3.75, p = 0.02).

Conclusions

One-year TLF and all-cause mortality were significantly higher in ACS than non-ACS patients treated with paclitaxel DCBs in real-world clinical settings. REGISTRATION Japan Registry of Clinical Trials (https://jrct.mhlw.go.jp); unique identifier: jRCT1032230218.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.